Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1632-1640

  Ghiringhelli, Francois ^a,b   Bichard, Damien ^c,d   Limat, Samuel ^c,d   Lorgis, Veronique ^a   Vincent, Julie ^a,b   Borg, Christophe ^c,d,e   Berthou, Julie ^c   Orry, David ^a   Ortega Deballon, Pablo ^b,f   Lakkis, Zaher ^d   Facy, Olivier ^b,f   Heyd, Bruno ^d   Rat, Patrick ^b,f   Nerich, Virginie ^c,d   Ladoire, Sylvain ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; COLORECTAL TUMOR; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; RETROSPECTIVE STUDY; VERY ELDERLY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL NEOPLASMS; FOLLOW UP; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84898844685     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3463-y     Document Type: Article

References (25)

1. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis. Lancet Oncol. 2007;8:898-911. (Pubitemid 47488054)
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-83.
3. O'Connell JB, Maggard MA, Ko CY, et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-5. (Pubitemid 39429665)
4. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721-7.
5. Chua TC, Saxena A, Liauw W, et al. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases - a systematic review. Eur J Cancer. 2012;48:1757-65.
6. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-86. (Pubitemid 350086481)
7. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225-32. (Pubitemid 350232254)
8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26:2013-9.
9. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14:29-37.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
11. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44. (Pubitemid 46733080)
12. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol. 2009;20:1842-7.
13. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326-34.
14. Abajo A, Bitarte N, Zarate R, et al. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol. 2012;18:637-45.
15. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8:210-21.
16. Levesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
17. Peeters CF, Westphal JR, de Waal RM, et al. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004;112:554-9. (Pubitemid 39425934)
18. Peeters CF, de Waal RM, Wobbes T, et al. Outgrowth of human liver metastases after resection of the primary colorectal tumor: A shift in the balance between apoptosis and proliferation. Int J Cancer. 2006;119:1249-53. (Pubitemid 44258796)
19. Scheer MG, Stollman TH, Vogel WV, et al. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med. 2008;49:887-91. (Pubitemid 351793428)
20. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011;18:3252-60.
21. Stillwell AP, Buettner PG, Ho YH, et al. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797-807.
22. Karoui M, Roudot-Thoraval F, Mesli F, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum. 2011;54:930-8.
23. Kim YW, Ko YT, Kim NK, et al. A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scand J Gastroenterol. 2010;45:217-25.
24. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
25. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-9.